Derma Sciences to Present at Two Upcoming Conferences
Barry J. Wolfenson, 609-514-4744Executive Vice President, Global Marketing and DevelopmentorKim Sutton Golodetz, 212-838-3777orBruce Voss, 310-691-7100@LHA_IR_PRorSpecOps CommunicaitonsMackenzie Mills, 212-518-7721 / Cell: 913-558-2492@SpecOpsComm
Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that Edward J. Quilty, the Company’s chief executive officer, will present a corporate overview and update at two conferences in December. They are:
To listen and view the presentations investors may visit the investor relations section of Derma Sciences’ website at . Archived copies of the presentations will also be available on Derma Sciences’ website.
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, an investigational pharmaceutical drug under development for the healing of diabetic foot ulcers, and is preparing to begin Phase 3 clinical trials. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, BIOGUARD® for infection prevention and TCC-EZ™, a gold-standard treatment for diabetic foot ulcers.
For more information please visit .